Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
TSHA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.05 - $4.32
Previous CloseN/A
Volume273.02K
Average Volume (3M)2.96M
Market Cap
$579.59M
Enterprise Value$360.91M
Total Cash (Recent Filing)$139.04M
Total Debt (Recent Filing)$63.18M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Aug 18, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding205,054,570
10 Day Avg. Volume4,483,072
30 Day Avg. Volume2,956,634
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)7.45
Price to Sales (P/S)0.00
P/FCF Ratio-5.35
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue7.97
Enterprise Value/Gross Profit43.31
Enterprise Value/Ebitda-0.69
Forecast
1Y Price Target
$6.94Price Target Upside157.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Taysha Gene Therapies News
See All TSHA News
---
Bulls Say, Bears Say
Bulls Say
Cash PositionThe company's cash position is expected to be sufficient into the fourth quarter of 2026, providing financial stability.
Financial PerformanceTSHA reported a net loss per share of ($0.08), which was better than the consensus estimate of ($0.09), showing a slightly better financial performance than expected.
Regulatory ProgressThe company has reached alignment and received written confirmation from the FDA on key elements of the pivotal Part B trial design, in line with what the company had initially been targeting.
Bears Say
EarningsTSHA reported a net loss per share of ($0.08), indicating financial challenges despite being better than expected.
Regulatory UncertaintyRemoving the need for an end of phase meeting reduces regulatory uncertainty for Taysha.
Trial DesignFDA alignment on pivotal design for TSHA-102 is a meaningful positive that limits looming uncertainty around acceptance of non-placebo controlled trials.
---
Ownership Overview
16.18% Insiders
12.50% Mutual Funds
39.19% Other Institutional Investors
24.03% Public Companies and
Individual Investors
TSHA FAQ
What was Taysha Gene Therapies’s price range in the past 12 months?
Taysha Gene Therapies lowest stock price was $1.05 and its highest was $4.32 in the past 12 months.
What is Taysha Gene Therapies’s market cap?
Taysha Gene Therapies’s market cap is $579.59M.
When is Taysha Gene Therapies’s upcoming earnings report date?
Taysha Gene Therapies’s upcoming earnings report date is Aug 18, 2025 which is in 92 days.
How were Taysha Gene Therapies’s earnings last quarter?
Taysha Gene Therapies released its earnings results on May 15, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.088 by $0.008.
Is Taysha Gene Therapies overvalued?
According to Wall Street analysts Taysha Gene Therapies’s price is currently Undervalued.
Does Taysha Gene Therapies pay dividends?
Taysha Gene Therapies does not currently pay dividends.
What is Taysha Gene Therapies’s EPS estimate?
Taysha Gene Therapies’s EPS estimate is -0.08.
How many shares outstanding does Taysha Gene Therapies have?
Taysha Gene Therapies has 205,054,570 shares outstanding.
What happened to Taysha Gene Therapies’s price movement after its last earnings report?
Taysha Gene Therapies reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.088. Following the earnings report the stock price went up 8.017%.
Which hedge fund is a major shareholder of Taysha Gene Therapies?
Currently, no hedge funds are holding shares in TSHA
---
Taysha Gene Therapies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.94 (157.04% Upside)
$6.94 (157.04% Upside)
Blogger Sentiment
Bullish
TSHA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 34.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.01%
12-Months-Change
Fundamentals
Return on Equity
-159.34%
Trailing 12-Months
Asset Growth
-9.57%
Trailing 12-Months
Company Description
Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
---
TSHA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, with significant regulatory progress and promising clinical data on TSHA-102 for Rett syndrome. The company is financially stable with a reduced net loss and decreased R&D expenses, although there was an increase in general and administrative costs.Read More>---
TSHA Stock 12 Month Forecast
Average Price Target
$6.94
▲(157.04% Upside)
Technical Analysis
Cartesian Therapeutics
―
Olema Pharmaceuticals
―
Monte Rosa Therapeutics
―
2seventy bio
―
MBX Biosciences, Inc.
―
---